Laura Sulzen

Concomitant Chemoradiotherapy as Primary Therapy for Locoregionally Advanced Head and Neck Cancer

Everett E. Vokes, Merrill S. Kies, Daniel J. Haraf et al. · Journal of Clinical Oncology · 2000 · 220 citations

Medicine, Oncology, Radiation Oncology +14

Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck.

Bruce Brockstein, D. Haraf, K. Stenson et al. · Journal of Clinical Oncology · 1998 · 72 citations

Medicine, Oncology, Radiation Oncology +17

A phase I–II study of concomitant chemoradiotherapy with paclitaxel (one-hour infusion), 5-fluorouracil and hydroxyurea with granulocyte colony stimulating factor support for patients with poor prognosis head and neck cancer

B. Brockstein, Daniel J. Haraf, Kerstin Stenson et al. · Annals of Oncology · 2000 · 45 citations

Medicine, Oncology, Pharmacology +17

Radiation Therapy With Concomitant Hydroxyurea and Fluorouracil in Stage II and III Head and Neck Cancer

Daniel J. Haraf, Merrill S. Kies, Alfred Rademaker et al. · Journal of Clinical Oncology · 1999 · 27 citations

Medicine, Oncology, Radiation Oncology +14

Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer.

Rod Humerickhouse, M. Eileen Dolan, Daniel J. Haraf et al. · PubMed · 1999 · 23 citations

Medicine, Oncology, Pharmacology +14